BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32781097)

  • 1. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
    Saberi Hosnijeh F; van der Straten L; Kater AP; van Oers MHJ; Posthuma WFM; Chamuleau MED; Bellido M; Doorduijn JK; van Gelder M; Hoogendoorn M; de Boer F; Te Raa GD; Kerst JM; Marijt EWA; Raymakers RAP; Koene HR; Schaafsma MR; Dobber JA; Tonino SH; Kersting SS; Langerak AW; Levin MD
    Exp Hematol; 2020 Sep; 89():55-60.e6. PubMed ID: 32781097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia.
    Saka B; Aktan M; Sami U; Oner D; Sanem O; Dinçol G
    Clin Lab Haematol; 2006 Feb; 28(1):30-5. PubMed ID: 16430457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
    Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
    Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia.
    Li H; Yi SH; Xiong WJ; Liu HM; Lyu R; Wang TY; Liu W; Zhong SZ; Yu Z; Zou DH; Xu Y; An G; Li ZJ; Qiu LG
    Chin Med J (Engl); 2017 Jan; 130(2):135-142. PubMed ID: 28091403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia.
    Sarfati M; Chevret S; Chastang C; Biron G; Stryckmans P; Delespesse G; Binet JL; Merle-Beral H; Bron D
    Blood; 1996 Dec; 88(11):4259-64. PubMed ID: 8943862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical Center.
    Falchi L; Keating MJ; Wang X; Coombs CC; Lanasa MC; Strom S; Wierda WG; Ferrajoli A
    Cancer; 2013 Sep; 119(17):3177-85. PubMed ID: 24022787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
    Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.
    Meuleman N; Stamatopoulos B; Dejeneffe M; El Housni H; Lagneaux L; Bron D
    Leukemia; 2008 Oct; 22(10):1882-90. PubMed ID: 18633433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
    Nabhan C; Raca G; Wang YL
    JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Assessment of selected markers of apoptosis and angiogenesis in chronic lymphocytic leukemia].
    Motyčková M; Smolej L; Andrýs C; Rezáčová V; Reháček V; Simkovič M; Belada D; Zák P
    Vnitr Lek; 2013 Sep; 59(9):782-93. PubMed ID: 24073950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia.
    Reinisch W; Willheim M; Hilgarth M; Gasché C; Mader R; Szepfalusi S; Steger G; Berger R; Lechner K; Boltz-Nitulescu G
    J Clin Oncol; 1994 Oct; 12(10):2146-52. PubMed ID: 7931486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
    Bühler A; Wendtner CM; Kipps TJ; Rassenti L; Fraser GA; Michallet AS; Hillmen P; Dürig J; Gregory SA; Kalaycio M; Aurran-Schleinitz T; Trentin L; Gribben JG; Chanan-Khan A; Purse B; Zhang J; De Bedout S; Mei J; Hallek M; Stilgenbauer S
    Blood Cancer J; 2016 Mar; 6(3):e404. PubMed ID: 26967821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia.
    Molica S; Vitelli G; Cutrona G; Todoerti K; Mirabelli R; Digiesi G; Giannarelli D; Sperduti I; Molica M; Gentile M; Morabito F; Neri A; Ferrarini M
    Int J Hematol; 2008 Nov; 88(4):374-380. PubMed ID: 18818986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
    Rassenti LZ; Huynh L; Toy TL; Chen L; Keating MJ; Gribben JG; Neuberg DS; Flinn IW; Rai KR; Byrd JC; Kay NE; Greaves A; Weiss A; Kipps TJ
    N Engl J Med; 2004 Aug; 351(9):893-901. PubMed ID: 15329427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis.
    Kara IO; Sahin B; Gunesacar R
    Adv Ther; 2007; 24(1):29-40. PubMed ID: 17526459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic lymphocytic leukemia: prognostic factors and impact on treatment.
    Parker TL; Strout MP
    Discov Med; 2011 Feb; 11(57):115-23. PubMed ID: 21356166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.
    Kaderi MA; Kanduri M; Buhl AM; Sevov M; Cahill N; Gunnarsson R; Jansson M; Smedby KE; Hjalgrim H; Jurlander J; Juliusson G; Mansouri L; Rosenquist R
    Haematologica; 2011 Aug; 96(8):1153-60. PubMed ID: 21508119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status.
    Baumann T; Delgado J; Santacruz R; Martínez-Trillos A; Rozman M; Aymerich M; López C; Costa D; Carrió A; Villamor N; Montserrat E
    Br J Haematol; 2016 Jan; 172(1):48-55. PubMed ID: 26559905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.